WO2010007622A3 - Long-acting interferons and derivatives thereof and methods thereof - Google Patents

Long-acting interferons and derivatives thereof and methods thereof Download PDF

Info

Publication number
WO2010007622A3
WO2010007622A3 PCT/IL2009/000700 IL2009000700W WO2010007622A3 WO 2010007622 A3 WO2010007622 A3 WO 2010007622A3 IL 2009000700 W IL2009000700 W IL 2009000700W WO 2010007622 A3 WO2010007622 A3 WO 2010007622A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
derivatives
long
acting interferons
interferons
Prior art date
Application number
PCT/IL2009/000700
Other languages
French (fr)
Other versions
WO2010007622A2 (en
Inventor
Fuad Fares
Udi Eyal Fima
Original Assignee
Modigene Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modigene Inc. filed Critical Modigene Inc.
Priority to CA2730996A priority Critical patent/CA2730996A1/en
Priority to AU2009272279A priority patent/AU2009272279A1/en
Priority to JP2011518058A priority patent/JP2011527904A/en
Priority to EP09797630A priority patent/EP2313431A4/en
Priority to CN2009801360213A priority patent/CN102171249A/en
Publication of WO2010007622A2 publication Critical patent/WO2010007622A2/en
Publication of WO2010007622A3 publication Critical patent/WO2010007622A3/en
Priority to IL210641A priority patent/IL210641A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an interferon (IFN) protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
PCT/IL2009/000700 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof WO2010007622A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2730996A CA2730996A1 (en) 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof
AU2009272279A AU2009272279A1 (en) 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof
JP2011518058A JP2011527904A (en) 2008-07-14 2009-07-14 Long-acting interferon and derivatives thereof and method thereof
EP09797630A EP2313431A4 (en) 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof
CN2009801360213A CN102171249A (en) 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof
IL210641A IL210641A0 (en) 2008-07-14 2011-01-13 Long-acting interferons and derivatives thereof and methods thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/216,989 2008-07-14
US12/216,989 US8048848B2 (en) 2006-02-03 2008-07-14 Long-acting interferons and derivatives thereof and methods thereof

Publications (2)

Publication Number Publication Date
WO2010007622A2 WO2010007622A2 (en) 2010-01-21
WO2010007622A3 true WO2010007622A3 (en) 2010-04-22

Family

ID=41550786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000700 WO2010007622A2 (en) 2008-07-14 2009-07-14 Long-acting interferons and derivatives thereof and methods thereof

Country Status (8)

Country Link
US (2) US8048848B2 (en)
EP (1) EP2313431A4 (en)
JP (1) JP2011527904A (en)
KR (1) KR20110049797A (en)
CN (1) CN102171249A (en)
AU (1) AU2009272279A1 (en)
CA (1) CA2730996A1 (en)
WO (1) WO2010007622A2 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
LT2717898T (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10010622B2 (en) 2011-07-08 2018-07-03 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
PT2814840T (en) 2012-02-15 2020-01-28 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
JP6383666B2 (en) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド Recombinant factor VIII protein
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
JP2015521589A (en) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Procoagulant compounds
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
MX363326B (en) * 2012-11-20 2019-03-20 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides.
EP3889173B1 (en) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimized factor viii gene
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
BR112016021777A2 (en) 2014-03-24 2017-10-03 Biogen Ma Inc LYOPHILIZED FACTOR IX FORMULATIONS
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
NZ733113A (en) 2014-12-10 2020-09-25 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
KR102172937B1 (en) 2015-06-19 2020-11-03 옵코 바이오로직스 리미티드 Long-acting coagulation factor and its preparation method
CN106397570B (en) * 2015-07-31 2019-11-15 袁武梅 A kind of carboxy terminal peptide and long-acting interferon
MX2018001497A (en) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
CN114835794A (en) * 2015-11-16 2022-08-02 Ubi蛋白公司 Method for extending the half-life of a protein
ES2926585T3 (en) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Optimized Factor VIII genes
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors.
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
BR112019015569A2 (en) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
KR20200118089A (en) 2018-02-01 2020-10-14 바이오버라티브 테라퓨틱스 인크. Use of lentiviral vectors expressing factor VIII
BR112020022164A2 (en) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. methods of treating hemophilia a
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
CN113797317B (en) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 Composition, and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080544A2 (en) * 2004-02-24 2005-09-01 Protalix Ltd. Cell/tissue culturing device, system and method
US7141547B2 (en) * 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US20070184530A1 (en) * 2006-02-03 2007-08-09 Fuad Fares Long-acting veterinary polypeptides and methods of producing and administering same
US7371373B2 (en) * 2001-04-09 2008-05-13 Novartis Vaccines And Diagnostics, Inc. HSA-free formulations of interferon-β

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3751873T2 (en) 1986-04-09 1997-02-13 Genzyme Corp Genetically transformed animals that secrete a desired protein in milk
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE110571T1 (en) 1988-05-06 1994-09-15 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
DK0461200T3 (en) 1989-02-21 1997-03-10 Univ Washington Modified forms of reproductive hormones
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
ATE187740T1 (en) 1993-04-20 2000-01-15 Univ Washington PHARMACEUTICAL AGENTS CONTAINING MODIFIED PROTEINS AND PEPTIDES
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
KR101229995B1 (en) 2000-12-11 2013-02-06 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
CA2680475A1 (en) 2000-12-28 2002-07-11 Shigeyuki Takada Sustained-release preparation
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2516339A1 (en) 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersing agent for sustained-release preparation
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
WO2005058347A1 (en) 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
ES2357132T3 (en) 2004-03-19 2011-04-19 Baxter International Inc. IXA FACTOR FOR THE TREATMENT OF HEMORRHAGICAL DISORDERS.
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8048848B2 (en) * 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371373B2 (en) * 2001-04-09 2008-05-13 Novartis Vaccines And Diagnostics, Inc. HSA-free formulations of interferon-β
US7141547B2 (en) * 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
WO2005080544A2 (en) * 2004-02-24 2005-09-01 Protalix Ltd. Cell/tissue culturing device, system and method
US20070184530A1 (en) * 2006-02-03 2007-08-09 Fuad Fares Long-acting veterinary polypeptides and methods of producing and administering same

Also Published As

Publication number Publication date
WO2010007622A2 (en) 2010-01-21
US20110286967A1 (en) 2011-11-24
US20090087411A1 (en) 2009-04-02
US8048848B2 (en) 2011-11-01
CA2730996A1 (en) 2010-01-21
AU2009272279A1 (en) 2010-01-21
AU2009272279A2 (en) 2011-08-11
JP2011527904A (en) 2011-11-10
CN102171249A (en) 2011-08-31
EP2313431A4 (en) 2012-01-04
EP2313431A2 (en) 2011-04-27
KR20110049797A (en) 2011-05-12
US8323636B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
WO2010007622A3 (en) Long-acting interferons and derivatives thereof and methods thereof
WO2007092252A3 (en) Long-acting polypeptides and methods of producing same
WO2011004361A3 (en) Long-acting coagulation factors and methods of producing same
WO2006051103A3 (en) Stable formulations of peptides
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2006031811A3 (en) Glycopegylated interferon alpha
WO2009155258A3 (en) Glucagon/glp-1 receptor co-agonists
PL1633390T3 (en) Stabilized pharmaceutical glp-1 peptide compositions
WO2005021022A3 (en) Stable formulations of peptides
WO2016203482A3 (en) Long-acting coagulation factors and methods of producing same
IL166699A0 (en) Peptides as solubilizing excipients for transforming groweth factor ? proteins
EA200602257A1 (en) STABILIZED LIQUID PREPARATIVE FORMS OF INTERFERON
WO2006110551A3 (en) Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
MX362446B (en) Long-acting coagulation factors and methods of producing same.
WO2008138649A3 (en) Signaling peptides
MX2009008241A (en) Glucagon/glp-1 receptor co-agonists.
EP1981979A4 (en) Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer
IL183346A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP3184640A3 (en) Protein body-inducing polypeptide sequences
WO2014080401A3 (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2008019368A3 (en) Albumin-insulin fusion proteins
UA93349C2 (en) Method of stabilizing interferon monomeric protein
EP1968635A4 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0510654A (en) interferon hydrogel formulations
IL186880A0 (en) Evolved interferon alpha polypeptides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980136021.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09797630

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 149/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011518058

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2730996

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009272279

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009797630

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117003288

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009272279

Country of ref document: AU

Date of ref document: 20090714

Kind code of ref document: A